- Hospital Consultants
- Associate Specialists and Specialist Trainees with an interest in Cardiovascular disease
- Caring Professionals
- Chemical Pathologists
- Clinical Lipidologists
- Vascular Surgeons
- Cardiovascular Radiologists
- Allied Health Professionals
- Community Pharmacists
- General Practitioners
- GPs with Specialist Interest in CVD
- Directors of Public Health
- Healthcare Commissioners
- Nurses - Specialist Cardiovascular and Lipid Clinic
- Nurses - Practice
- Nurses - Genetics Specialist
- Basic Scientists
- Scientists and researchers in cardiovascular diseases
- Those with an interest in cardiovascular disease, lipids and atherosclerosis
'Hot Topics in Atherosclerosis and Cardiovascular Disease'
Read more details on the programme by clicking on the links below.
Wednesday 4 - Friday 6 July 2018
TOPICS + SPEAKERS - Wednesday 4 July:
- Optimising treatment of Hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines
Evidence strongly favours therapeutic LDL concentration targets in hypercholesterolaemia
Professor Paul DURRINGTON (Manchester, UK)
- Cardiovascular risk in chronic kidney disease and its management
Professor Phil KALRA (Manchester, UK)
- Lipodystrophy: diagnosis and management
Diagnosis and management of syndromes of lipodystrophy
Dr Anna STEARS (Cambridge, UK)
- Lipoprotein(a): its value as a CV risk factor and how to address it
Describing the role of lipoprotein(a) as an independent risk factor for atherosclerotic disease and discuss potential treatments
Professor Klaus G. PARHOFER (Munich, GERMANY)
- Lp(a) in children
Professor Kurt WIDHALM (Vienna, AUSTRIA)
- Lipoprotein (a) as a therapeutic target
Dr Tina KHAN (London, UK)
- Lp(a) – The Lipoprotein(a) Foundation, a risk marker for cardiovascular disease – A patient’s story
The Vision of the Lipoprotein(a) Foundation is to live in a world where high Lipoprotein(a) is routinely diagnosed, treated and family screened.
Mrs Sandra REVILL TREMULIS (San Carlos, California, USA)
- Symposia session 1 - Sanofi
- Symposia session 2 - Akcea
- Symposia session 3 - Amgen
TOPICS + SPEAKERS - Thursday 5 July:
- CETP inhibition – the Oxford REVEAL study
This talks will describe the story of CETP inhibition to date, and the results of the 30,000-patient REVEAL trial of anacetrapib.
Dr Louise BOWMAN (Oxford, UK)
- HDL – reasons of previous clinical futility and opportunities for future clinical utility
Exploitation of HDL needs novel biomarkers that unlike “HDL-cholesterol” reflect functionality of HDL
Professor Arnold VON ECKARDSTEIN (Zurich, SWITZERLAND)
- Inflammation in atherosclerosis and coronary artery disease
Inflammation in coronary arteries, does it matter and what can be done about it?
Professor Sheila FRANCIS (Sheffield, UK)
- Inclisiran – the story so far
Exploring the mechanism of action of inclisiran, data from early phase trials, details of ongoing studies and plans for a forthcoming cardiovascular outcome trial.
Dr David PREISS (Oxford, UK)
- Non alcoholic fatty liver disease (NAFLD) update
NAFLD is very common in patients with CVD risk factors: how should NAFLD be diagnosed and which patients should be referred for specialist investigation?
Professor Christopher D BYRNE (Southampton, UK)
- Bariatric surgical approaches in managing obesity
Mr John BARRY (Swansea, Wales, UK)
- Metabolic improvements in patients with impaired glucose homeostasis following bariatric surgery
Professor Jeffrey STEPHENS (Swansea, Wales, UK)
- Public health and primary care commissioning for vascular health
Mrs Gillian FIUMICELLI (London Borough of Bromley, UK)
- Cardiovascular disease: lifetime risk for women
Awareness of recommendations for women’s cardiovascular health and an individualised approach may lead to equitable provision; recent SWEDEHEART data 2003-2013 question progress and must keep us vigilant.
Dr Jane FLINT BRIDGEWATER (Dudley, UK)
- Men and CVD
There is a gender gap of 6-7 yrs. in favour of women, why should that be???
Professor Michael KIRBY (Hatfield, UK)
- Clinical Lipidology Live – Interactive case study session in a panel format with perspectives from a cardiologist, lipidologist and GP
- HEART UK charity update
Miss Jules PAYNE
- KEYNOTE MYANT LECTURE:
Nuclear receptors in the control of metabolic and cardiovascular disease
Nuclear receptors as therapeutic targets for cardiometabolic diseases – a story from bench-to-bedside
Professor Bart STAELS (Lille, FRANCE)
Heart healthy walk
TOPICS + SPEAKERS - Friday 6 July:
- Poster session (moderated + unmoderated)
- Abstracts of free communications - oral session
- Genomics Update
- Cutting dietary sugar in primary care: Effect on lipid profiles, liver function, blood pressure, Type 2 Diabetes control and drug budgets
Is cutting sugar a magic bullet? Find out how my GP practice gets great results, spends £38,000 less on drugs for diabetes alone and works with patients’ goals.
Dr David UNWIN (Southport, UK)
- Vascular dementia
Dr Bernadette MCGUINNESS (Belfast, N Ireland)
- Closing Interactive Session:
This house believes that Dyslipidaemia rather than Glycaemic control is the major determinant of CVD risk in the patient with T2DM.
Presentation of prizes and awards
The conference is sponsored by various organisations. These organisations have had no input into the development of the programme for the study day, Medical & Scientific and Healthcare programme’s, or influenced the choice of speakers. But excluding the sponsored symposia sessions where the programme is developed and speakers identified by the sponsor.